CNR1 and Cognitive impairment: The first example of such transition shows that the analgesic properties of cannabinoids can be exploited while keeping their adverse side reactions (i.e., psychoactive effects and cognitive impairment) at bay by co-administration with a novel optimized CB1R-5HT2AR heterodimer-disrupting peptide.